Advances in Combination Therapy for Gastric Cancer: Integrating Targeted Agents and Immunotherapy
Jun Ren
Abstract
Background: Despite the recent advancement in the diagnostic and therapeutic approaches, gastric cancer continues to be one of the most cardinal causes of the cancer death globally. Trends of the recent years in composite treatments that integrate biomarkers with immunotherapy along with well-tailored and individualized aggregate remedies introduce perspectives for the optimization of the outcomes. Objective: The present review intends to qualify to give as much and more than a very comprehensive update on the latest developments of the pool of targeted agents and immunotherapy for gastric cancer, focusing on the mechanisms, medical trial effects, and future directions. Methods: The papers for the review were identified through a comprehensive search of both PubMed as well as other databases represented in the actual journals. The filter used for search was the actual last 10 years. As for the criteria for inclusion on the studies it was only the relevance of the material, and their experience on combination remedies in gastric cancers. Results: The combination of the former therapies, namely the human epidermal growth factor receptor 2 (HER2 inhibitors), Vascular Endothelial Growth Factor (VEGF) inhibitors, and mesenchymal-epithelial transition (MET) inhibitors has demonstrated better efficiency in various clinical trials not to mention having the right immune checkpoint inhibitors. The most important findings of current literature suggest that there is presumably cooperative interaction of all of these components, which results in more accurate anti-tumor reactions and better survival rates. Conclusion: The inclusion of combination therapy should be highly included into recommended treatment plans for gastric cancer, especially for patients with certain molecular profiles. The evidence suggests that the combination of targeted treatment programs with immunotherapy provides significant advantages compared to typical monotherapy approaches, including increased effectiveness and improved overall survival rates.